Background. We assessed whether a near-infrared spectroscopy (NIRS)-based algorithm for the personalized optimization of cerebral oxygenation during cardiopulmonary bypass combined with a restrictive red cell transfusion threshold would reduce perioperative injury to the brain, heart, and kidneys. Methods. In a randomized controlled trial, participants in three UK centres were randomized with concealed allocation to a NIRS (INVOS 5100; Medtronic Inc., Minneapolis, MN, USA)-based 'patient-specific' algorithm that included a restrictive red cell transfusion threshold (haematocrit 18%) or to a 'generic' non-NIRS-based algorithm (standard care). The NIRS algorithm aimed to maintain cerebral oxygenation at an absolute value of > 50% or at > 70% of baseline values. The primary outcome for the trial was cognitive function measured up to 3 months postsurgery.
Near-infrared spectroscopy (NIRS) is a non-invasive method for the measurement of regional cerebral oxygenation and has been shown to reflect cerebral mixed venous oxygen saturations in cardiac surgery patients. 4 It has been hypothesized that personalized goal-directed interventions directed towards increasing regional brain oxygen saturation as measured by NIRS during CPB might lead to reductions in brain injury 4 or reductions in injury to other organs, including the heart and kidneys, as a consequence of improved overall perfusion. 5 It has also been postulated that NIRS might be used to personalize transfusion decisions, whereby red cell transfusions are used as one component of a patient-specific algorithm designed to optimize tissue oxygenation. 6 To test these hypotheses and to address clinical uncertainty regarding the benefits of NIRS-based algorithms 7 reflected by variability in their use, 8 we performed a multicentre randomized controlled trial comparing a personalized goal-directed NIRS-based algorithm that incorporated a restrictive red cell transfusion threshold vs standard care in adult patients undergoing heart valve surgery with or without coronary artery bypass grafting (CABG). The primary outcome for the trial was cognitive function measured up to 3 months postsurgery. Secondary outcomes included biomarkers of brain, kidney, and myocardial injury, adverse events, and resource use.
Methods

Trial design and participants
The effects of patient-specific cerebral oxygenation monitoring as part of an algorithm to reduce red cell transfusion in patients having heart valve surgery (PASPORT) trial (registration ISRCTN 23557269 on February 27, 2009) was a parallel-group randomized controlled trial conducted at three cardiac surgery centres in the UK. Male and female adult patients undergoing open valve or combined CABG and open valve surgery were eligible. Table S1 , included patients with pre-existing neurological disease or inflammatory states. Participants provided written informed consent before surgery but became eligible for randomization only if they scored !24 on the Mini Mental State Examination (indicating no cognitive impairment). The allocated intervention was applied during CPB. Participants were followed up until discharge and at 6 weeks and 3 months after randomization. The trial complied with the Declaration of Helsinki. A UK National Health Service (NHS) Research Ethics Committee (REC) approved the study (09/H0102/13) on June 15, 2009 . A detailed protocol has been reported elsewhere. 9 University Hospitals Bristol NHS Trust was the trial sponsor. Changes to the trial after commencement are described in the Supplementary material.
Exclusions, listed in Supplementary material
Randomization and blinding
Participants were randomly allocated to either the 'generic' or 'patient-specific' algorithms for optimizing tissue oxygenation during CPB in a 1:1 ratio, stratified by centre and surgical procedure (valve only or combined CABG and valve). Allocations, blocked with varying block sizes, were generated by computer and concealed using a secure password-protected internet-based randomization system. Randomization occurred before surgery after written informed consent was given and eligibility confirmed and as close to the planned surgery time as possible. Patients and outcome assessors were blinded to group allocation.
Interventions
The trial compared two algorithms for optimizing tissue oxygenation during CPB, generic and patient-specific algorithms. The interventions were defined as follows.
Generic algorithm (including a standard transfusion threshold)
This was a generic algorithm for optimizing tissue oxygenation based on global measures of oxygen utilization and including a predefined intraoperative haematocrit transfusion threshold of 23%.
Patient-specific algorithm (including a restrictive transfusion threshold)
This was a patient-specific, goal-directed algorithm based on the monitoring and optimization of regional cerebral oxygen saturation measured using the INVOS 5000 NIRS device (Somanetics, IN, USA), combined with a predefined 'restrictive' intraoperative haematocrit transfusion threshold of 18%. Optimization of cerebral oxygenation used a modified Murkin protocol 10 (see Supplementary Table S2 ) that aimed to maintain INVOS values at an absolute value of >50% or at >70% of baseline values obtained in the anaesthetic room before induction whilst breathing room air. If target cerebral oxygenation values were not achieved by modifying aspects of pump flow, gas exchange, or depth of anaesthesia as specified in the algorithm, red cells could be transfused above the 18% haematocrit threshold. Details of perioperative care protocols, monitoring of protocol compliance, blinding of clinical staff, and other steps to mitigate bias are described in the Supplementary material.
Editor's key points
• Personalized optimization of cerebral oxygen saturation during cardiac surgery may reduce perioperative neuronal injury.
• One manoeuvre for optimization is blood transfusion, which poses its own risks.
• The authors developed an optimization protocol involving a transfusion threshold of haematocrit 18%.
• Cognitive outcomes were similar with this protocol compared with a generic protocol (no near-infrared spectroscopy optimization, haematocrit threshold 23%).
Assessed for eligibility (n=764)
Patients excluded (n=556) Ineligible (n=135) 1 
Outcomes
Timings of outcome assessment are listed in Supplemental  Table S3 .
Primary outcome
The primary outcome for the trial was serial measures of cognitive function on or between 4 and 7 days after surgery and again at 3 months. 11 12 Cognitive function was assessed by qualified examiners, trained in the methods of neurocognitive assessment used in the study and blinded to treatment allocation before surgery. The following cognitive domains were tested.
• Attention: sustained and divided attention: trail-making test parts A and B.
• Verbal memory: Rey Auditory Verbal Learning Test.
• Visuo-spatial: block design from the Wechsler Adult Intelligence Scale.
• Psychomotor speed: digit symbol test from the Wechsler Adult Intelligence Scale-Revised test.
• Executive function/verbal fluency: controlled oral word association test.
• Motor coordination: grooved pegboard test, dominant and non-dominant hand.
To help interpret the cognitive function data, the following assessments were carried out for all participants.
• The Wechsler Test of Adult Reading (WTAR) provided a measure of intellectual ability, before surgery only.
• Documentation of medications known to interfere with neuropsychological functions was carried out before and after surgery.
• Assessment of the patient's current mental health was done using the General Health Questionnaire (GHQ-30) and Hospital Anxiety and Depression Scale (HADS) before and after surgery, to take into account the potential interaction between postoperative cognition and mood. Table S4 ).
Secondary outcomes
Sample size
We estimated that a sample size of 75 participants per group would be sufficient to detect small-to-moderate standardized differences between the two groups of 0.33 for the primary outcome cognitive function (adjusting for baseline) and 0.4 for inflammation and organ injury biomarkers (adjusting for baseline and using four repeated measures) with 80% power and 5% significance (two tailed). Correlations between repeated measures were assumed to be 0.7. For time to cardiac intensive care unit or hospital discharge, the sample size allowed a hazard ratio (HR) of 1.65 to be detected. During the trial, at the request of the funder, the sample size was increased to 100 patients per group because of a higher than expected dropout rate and a lower than expected correlation between baseline and postintervention cognitive function (no comparison between groups was made when the sample size assumptions were reviewed).
Statistical analysis
The analysis population included all randomized participants, excluding patients who died or withdrew after randomization but before surgery. Outcomes are reported by intention to treat and were directed by a prespecified statistical analysis plan (see Supplementary material). Continuous variables are summarized using the mean (SD), or the median and interquartile range (IQR) if the distribution is skewed, and categorical data are summarized as a number and percentage. Near-infrared spectroscopy was summarized as an area under the curve (AUC), as described in detail in the Supplementary material. Primary and secondary outcomes were compared using linear mixed model (continuous variables measured at multiple time points), multiple (continuous variables summarized as a single measurement), logistic (binary variables), or Cox proportional hazards (time to event variables) regression, with the generic algorithm as the reference group. All analyses were adjusted for the stratification variables, centre, and surgical procedure. Treatment effect estimates are reported with 95% confidence intervals (CIs). Likelihood ratio tests were used to determine statistical significance, and two tailed P-values <0.05 were considered statistically significant. Neurocognitive outcomes were adjusted for the stratification variables and for reading ability at Continued recruitment, medication, and preoperative GHQ-30, HADSAnxiety and HADS-Depression scores. The overall treatment effect for the primary outcome and for other continuous outcomes measured at repeated time points was estimated across the postsurgery time points, with adjustment for baseline differences. Where there was a significant timeÂtreatment interaction effect, estimates were calculated at each time point. Significant differences in either the overall effect or for individual time points were considered evidence of a treatment effect for that outcome. For the primary outcome, it was specified in the statistical analysis plan that four out of six domains significant at the 5% level would provide evidence to support the study hypotheses. The trial was not powered to detect differences in clinical outcomes, and their frequencies are tabulated descriptively.
All analyses were performed in SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and Stata version 13.0 (StataCorp LP, College Station, TX, USA).
Results
Trial cohort and patient flows
The flow of patients through the trial is shown in Fig. 1 . Two hundred and eight patients were recruited and randomized between December 2009 and January 2014. Four patients withdrew before surgery. The analysis population therefore comprised 204 participants, 106 of whom were allocated to the generic algorithm and 98 to the patient-specific NIRS algorithm. Of the 204 randomized patients, 194 were eligible for follow-up at 3 months, and 175 completed the 3 month questionnaire and attended for the neurocognitive assessment, (n¼87 generic algorithm, n¼88 patient-specific algorithm). Details of patient withdrawals are listed in Supplementary Table S5 . There were 30 protocol deviations; 11 in the generic algorithm group and 19 in the patient-specific algorithm group (Supplementary Table S6 ).
Participant characteristics
Baseline characteristics were similar in the two groups ( Table 1) . The mean age of participants was 68 (SD 11) yr, and 69% were male. The median EuroScore was 5 in both groups. Overall, 157 (77%) participants were listed for valve surgery and 47 (23%) for combined CABG and valve surgery. Bypass, cross-clamp, and the overall duration of the surgery were similar in the two groups (Supplementary Table S7 ). All participants were alive at the end of the surgery.
Primary outcome
The results of the neurocognitive tests are shown in Table 2 . The scores for the cognitive domains attention, verbal memory, visuo-spatial skills, psychomotor speed, and visual motor coordination were similar between the groups. Effect estimates were not significantly altered by adjustment for medications and mental health during follow-up. For the executive function/verbal fluency domain, mean scores were significantly better in the patient-specific algorithm group [mean difference (MD)¼2.72 (95% CI 0.64, 4.80)], which increased when accounting for medication and mental health both at baseline and during follow-up [MD ¼ 3.73 (95% CI 1.50, 5.96)]. These differences did not meet the prespecified definition of a reduction in cognitive dysfunction. 
Secondary outcomes
Results for the secondary outcomes are shown in Figs 2 and 3 and in Supplementary Table S8 Tables S10 and S11) . Biomarker concentrations were similar in the two groups for inflammation (IL-6, IL-8), brain (serum S100), myocardial (serum troponin T), or kidney injury ( Fig.  3 and Supplementary Fig. S2 , Table S12 and Table S13 ).
Discussion
Main findings
The results of the PASPORT trial do not support the hypothesis that a patient-specific NIRS-based algorithm for the management of CPB results in reductions in neurocognitive dysfunction at up to 3 months postsurgery. Use of NIRS did not result in perioperative reductions in serum or urine biomarkers of brain, kidneys, and myocardial injury, or in resource use.
Strengths and limitations
The PASPORT trial compared a widely used patient-specific NIRS-based algorithm with standard care in three UK centres where this technology is in common use for the optimization of tissue oxygenation during CPB. It used detailed neurocognitive assessments and complementary clinical measures and biomarkers of injury and dysfunction in multiple organ systems. The principal limitation of the trial was the limited blinding of health-care personnel; only the researchers responsible for the assessment of the neurocognitive and clinical outcomes and the laboratory staff carrying out the biomarker assays were blinded. We addressed this by documenting protocol compliance. This demonstrated that the nature of protocol nonadherence differed by group and also that the proportion of patients with non-adherence to the Murkin protocol in the intervention group was high (18%). This occurred despite all the members of the clinical team at each of the recruiting centres being familiar with the technology before conducting the trial. High levels of protocol non-adherence have been reported in a similar trial. 13 Although we cannot exclude the possibility that this may have introduced bias, it is equally possible that we have measured the normal application of this technology in a complex and highly variable operating theatre environment. Another limitation is that the trial recruited throughout a prolonged period. It is possible that refinements in care may have occurred during this period, although as these changes will have been reflected in the trial cohort, this also increases the relevance of the findings to contemporary practice.
Clinical relevance
We detected a significant difference in one neurocognitive domain, executive function/verbal fluency, which favoured the patientspecific NIRS group. However, this is not a core domain as defined by the Consensus Statement for the Assessment of Neurocognitive function in Cardiac surgery, 11 and we did not conclude that this was sufficient to demonstrate efficacy. We also consider it unlikely that alternative definitions of neurocognitive dysfunction, such as the composite Z score, would have altered our findings. This conclusion was supported by no significant difference between the groups for the brain injury biomarker S100B. The NIRS levels were similar in both groups, with relatively few patients experiencing cerebral desaturation. We suggest that this may have contributed to our clinical findings; low frequencies of cerebral desaturation reduce the likelihood that NIRS-based algorithms will have clinical utility. This is perhaps attributable to the supranormal levels of oxygen delivery during CPB measured in the study; almost no patient had values approaching critical oxygen delivery (<500 ml min
À1
). Important risk factors for neurocognitive dysfunction, such as increased age, diabetes, or poor left ventricular function, were also uncommon, and this may have influenced our results. The potential for NIRS to contribute to cerebral protection will also have been influenced by the presence or absence of other factors that we did not quantify, such as cerebral emboli or preexisting white matter changes.
14 Finally, our findings refuted the hypothesis that a patient-specific algorithm that aims to optimize cerebral NIRS values may have additional important benefits for other organs, such as the heart and kidneys. 
Conclusions
We did not demonstrate a clinical benefit for personalized, NIRSdirected management of patients during CPB. 4 These devices are in widespread use. 8 It is possible that our results are attributable to chance, although we detected no difference between NIRS and standard-care groups using multiple tests and assays that are sensitive markers of injury to a range of organ systems. Alternative hypotheses are that cerebral oxygen saturation measured by NIRS does not reflect cerebral oxygen utilization, 15 or that cerebral hypoxia is not the principal cause of post-CPB brain injury. 14 These findings support ongoing efforts to identify measures of cellular oxygen uptake 16 that may have clinical utility.
